European annals of allergy and clinical immunology最新文献

{"title":"Factors effecting natural course of egg allergy.","authors":"H Duman Şenol, M Geyik, E Topyıldız, A Aygün, F Gülen, E Demir","doi":"10.23822/EurAnnACI.1764-1489.287","DOIUrl":"10.23822/EurAnnACI.1764-1489.287","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> There is limited data about the natural course of egg allergy in the literature. We aimed to analyze the factors that can affect the tolerance or persistence of egg allergy. <b>Methods.</b> A total number of 126 IgE- mediated egg allergic patient who had data about tolerance gaining were included in the study. Demographic and laboratory data were recorded retrospectively. Kaplan-Meier curves was used for estimation of resolution and the factors related to resolution by Cox regression model. <b>Results.</b> Among 126 patients 81 (64.2%) had gained tolerance with a median survival time of 48 months (min 12- max 121). Tolerance was gained in 22.2% (28) of these patients in the first 2 years, in 46.8% (49) 2-6 years, 3.1% (4) between 7-12 years. In univariate analysis, no history of anaphylaxis (at initiation or during OFC) (Hazard ratio 2.193; 95%CI 1.309-3.674, p = 0.003), baseline sIgE level less than 8.2 (Hazard ratio 11.292; 95%CI 2.766-46.090, p = 0.001) and baseline egg SPT less than 11 mm (Hazard ratio 2.906; 95%CI 1.424-5.930, p = 0.003) were found to be related to earlier resolution of egg allergy. In multivariate analysis only anaphylaxis was significantly related to later resolution (Hazard ratio: 6.547; 95%CI 15.80-27.434, p = 0.01). <b>Conclusions.</b> Higher levels of egg sIgE, skin prick test induration and anaphylaxis at onset or during oral food challenge, can give hint about persistence of egg allergy.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"116-120"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10154642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of pain-alleviating strategies during allergy shots (subcutaneous immunotherapy): a randomized controlled pilot study.","authors":"J Pfieffer, K Wehmeier, K Gee, T DeSanto, E Yousef","doi":"10.23822/EurAnnACI.1764-1489.312","DOIUrl":"10.23822/EurAnnACI.1764-1489.312","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Subcutaneous immunotherapy (SCIT) is a potential disease-modifying therapy effective for treatment of various allergic disorders. Pain and fear are common concerns of children, which can pose stress and result in negative experiences. The purpose of this study was to evaluate and compare the effectiveness of three marketed distraction devices and ethyl chloride spray (a routinely used topical anesthetic agent for painful procedures), the current clinical standard of care in reducing the perception of needle pain during SCIT administration in children. <b>Methods.</b> 40 children, aged 4-17 years, receiving SCIT with use of one of three alternative pain therapies or with standard practice were enrolled. Participants were randomly assigned to one of the pain-modifying interventions. The three interventional groups were ShotBlocker^® (Bionix, Toledo, OH, USA), Buzzy^® I (Pain Care Labs, Atlanta, GA, USA) (vibration only), and Buzzy^® II (vibration with ice). Control group was ethyl chloride spray. The study consisted of two visits during SCIT administration process. <b>Results.</b> Of these 40 children, 12 received the ShotBlocker, 8 received the Buzzy I, 11 received the Buzzy II, and 9 received ethyl chloride spray (control group). <b>Conclusions.</b> There were no significant differences found between each of the distraction devices and between the control group. Type II error/false negative finding cannot be ruled out because of a small sample. Therefore, we cannot conclude that no true difference exists between each distraction device and the control group simply because of occurrence of a non-significant P-value in our study.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"128-136"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10161747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic status and thyroid autoimmunity do not predict omalizumab response in severe chronic spontaneous urticaria patients.","authors":"S Asero","doi":"10.23822/EurAnnACI.1764-1489.283","DOIUrl":"10.23822/EurAnnACI.1764-1489.283","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"141-143"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10699852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the outcome of the buckwheat oral challenge test: a first evaluation assuming a single serving of boiled buckwheat noodles.","authors":"K Horimukai, M Kinoshita, N Takahata","doi":"10.23822/EurAnnACI.1764-1489.315","DOIUrl":"10.23822/EurAnnACI.1764-1489.315","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Global increase in buckwheat consumption has led to a surge in buckwheat allergy reports. However, studies scrutinizing the predictive accuracy of buckwheat-specific immunoglobulin E (IgE) antibody levels in correlation with symptom manifestation remain limited. A critical concern is the discrepancy between the total buckwheat amount featured in prior studies and the quantity consumed per occasion. We aimed to determine open Oral Food Challenge (OFC) positivity rates with buckwheat, using a single serving of boiled buckwheat noodles, and assess the predictability of positive responses using buckwheat-specific IgE levels. <b>Methods.</b> Patients aged 20 years or younger, suspected of buckwheat allergy, were subjected to an OFC involving consumption of 100 g (4,800 mg of protein) of boiled buckwheat noodles for those under six years, and 200 g (9,600 mg of protein) for those six years or older. The predictive accuracy of the OFC, corresponding with buckwheat-specific IgE antibody levels, was evaluated using Receiver Operating Characteristic (ROC) analysis. <b>Results.</b> Our study involved 80 patients who undertook a buckwheat OFC. Among these, 14 (17.5%) tested positive for a buckwheat allergy, with 3 (3.8%) developing anaphylaxis. The comparative analysis of buckwheat-specific IgE antibody levels did not offer a reliable predictive measure for OFC outcomes. However, a past history of symptom manifestation following buckwheat consumption was significantly correlated with a positive OFC. <b>Conclusions.</b> Forecasting OFC outcomes based on buckwheat-specific IgE antibody levels poses a challenge, even when taking into account the total quantity of buckwheat that can be consumed in a single occasion.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"121-127"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10298187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab to induce tolerance to SLIT-Melocotón®.","authors":"M S Zamarro Parra, Y Petryk Petryk, S San Román Sirvent, C Navarro Garrido, A I Escudero Pastor, J C Miralles López, A Carbonell Martínez","doi":"10.23822/EurAnnACI.1764-1489.280","DOIUrl":"10.23822/EurAnnACI.1764-1489.280","url":null,"abstract":"<p><strong>Summary: </strong>Food allergy is an increasing problem for population, and treatments inducing tolerance using sublingual immunotherapy is currently under study. Our aim as allergists is to achieve tolerance to sublingual allergen specific immunotherapy with sublingual immunotherapy (SLIT-peach). We present a case report consisting of a 40-year-old woman with anaphylactic reactions after eating fruit and other plant-foods due to sensitization to nonspecific lipid transfer proteins (nsLTP). Her diagnose was LTP-syndrome. This protein is the main pannallergen in our area and causes crossed reaction to multiple plant foods. The principal allergen in this syndrome is rPru p3, present in peach and most vegetables, fruits, nuts and grains. Serum specific IgE levels were performed using microarrays and positive for seven nsLTPs: rAra h9, rCor a8, nJug r3, rPru p3, rTri a 14, nArt v3 and rPla a3. Immediate reaction to SLIT in the fourth month of maintenance-dose led us to interrupt pru p3 immunotherapy. Immediate reaction to omalizumab in the fourth dose in hospital consisting in anaphylaxis prompted us to switch to dupilumab. After four months with this monoclonal antibody, we reintroduced sublingual immunotherapy with pru p3 SLIT-peach^® achieving maintenance dose of four drops a day with no clinical reactions. SLIT-peach^® in our patient is crucial for her due to her restricted diet, the severity of reactions and lack of quality of life measured by Europevall questionary. There are no cases reported for dupilumab in this use.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"137-140"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9072718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Probiotics, prebiotics and food allergy: a review.","authors":"J F Ribeiro, C Pedrosa","doi":"10.23822/EurAnnACI.1764-1489.319","DOIUrl":"10.23822/EurAnnACI.1764-1489.319","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> The review was structured in the following sections: 1) Cow's Milk Proteins Allergy (CMA), 2) Food Allergy to Peanuts and 3) Prevention of Food Allergy. In CMA, studies indicate that extensively hydrolyzed casein formula supplemented with <i>Lactobacillus Rhamnosus</i> GG aids in acquiring tolerance to cow's milk proteins, resolving gastrointestinal symptoms and preventing of other allergic manifestations. In peanut oral immunotherapy (OI), supplementation with <i>Lactobacillus Rhamnosus</i> CGMCC 1.3724 appears to promote sustained desensitization. However, the evidence supporting probiotics for preventing food allergies lacks robustness. Current evidence supports the use of oligosaccharides from breast milk in the first months of life for preventing atopic dermatitis, FA and asthma <b>Methods.</b> A PubMed/Medline search was carried out on articles published between 2011 and 2021 with the following query: (\"Food Hypersensitivity\"[Mesh]) AND ((\"Probiotics\"[Mesh]) OR (\"Prebiotics\"[Mesh])). Subsequently, the titles and abstracts were analysed and selected according to established criteria. After full reading of these articles, 54 were included and a narrative review was performed. <b>Results.</b> The review was structured in the following sections: 1) Cow's Milk Proteins Allergy (CMA), 2) Food Allergy to Peanuts and 3) Prevention of Food Allergy. In CMA, studies indicate that extensively hydrolyzed casein formula supplemented with <i>Lactobacillus Rhamnosus</i> GG aids in acquiring tolerance to cow's milk proteins, resolving gastrointestinal symptoms and preventing of other allergic manifestations. In peanut oral immunotherapy (OI), supplementation with <i>Lactobacillus Rhamnosus</i> CGMCC 1.3724 appears to promote sustained desensitization. However, the evidence supporting probiotics for preventing food allergies lacks robustness. Current evidence supports the use of oligosaccharides from breast milk in the first months of life for preventing atopic dermatitis, FA and asthma. <b>Conclusions.</b> The potential of probiotics to be used as therapeutic adjuvants in CMA and peanut OI is promising. However, there is inconsistency regarding the type of probiotic, the dose and duration of supplementation. Further studies are needed to clarify the role of probiotics and prebiotics in FA.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"99-110"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey.","authors":"C Lombardi, G Passalacqua, F Menzella, R F Mauritz Canevari, G Danesi, A M Pusateri, M Carone, C Vancheri, F Di Marco, C Micheletto, G Manzotti, M Di Gioacchino, M B Bilò, M Gelardi, G Senna, G W Canonica","doi":"10.23822/EurAnnACI.1764-1489.338","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.338","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic rhinosinusitis (CRS) is an inflammatory disease that affects the nasal mucosa and the paranasal sinuses. CRS can be associated by nasal polyposis (CRSwNP phenotype) in up to 30% of patients and it is frequently associated with bronchial asthma. CRSwNP shows predominantly an underlying activation of type 2 inflammatory pathways with the involvement of eosinophils, IgE, interleukin (IL)-4, IL-5 and IL-13. Biological drugs that target these inflammatory cytokines are currently a therapeutic option recognized by guidelines for the treatment of uncontrolled form of the disease. <b>Methods.</b> As part of the activity of the \"ARIA-Italy\" working group, a panel of 255 Italian Ear, Nose and Throat (ENT) specialists, pneumologists and immuno-allergologists actively participated in this national survey and answered a series of questions geared toward understanding the main criteria for patient characterization and therapeutic decision, highlighting multidisciplinarity, and the implementation of the management of CRSwNP patients, as a part of the precision medicine concept and the appropriate use of the biologicals. <b>Results.</b> Two hundred and fifty-five experts and specialists participated in the survey. <b>Conclusions.</b> The results of this survey obtained from an extensive number of active specialists throughout Italy allow some important concluding remarks to be drawn. The main points of agreement were that multidisciplinary care teams provide many benefits but that, once the team is established, meetings and communication between members must be coordinated. Finally, the dissemination of national disease registries and the continuous updating of guidelines and position papers related to CRSwNP and comorbidities should be encouraged.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study.","authors":"A Palladino, F Villani, E Pinter, M Visentini, R Asero","doi":"10.23822/EurAnnACI.1764-1489.337","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.337","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic spontaneous urticaria (CSU), characterized by recurrent itchy wheals and angioedema for > 6 weeks, is a quite common disease that may heavily impair the quality of life. Omalizumab, an anti-IgE mAb, has much improved the management of CSU but patients' response to the drug may vary and predictive markers are still largely missing. We investigated the predictive value of the autologous serum skin test (ASST) on omalizumab response. <b>Methods.</b> 15 patients with severe CSU eligible for omalizumab treatment were prospectively studied submitting them to ASST and to complete blood count, D-dimer, anti-thyroid peroxidase antibodies, and total IgE measurement before the start of the treatment. <b>Results.</b> 14/15 (93%) responded brilliantly to omalizumab at 3 months assessment. 7 responded in less than 1 month (\"early responders\") and 7 only after multiple administrations (\"late responders\"). Of 9 patients scoring positive on ASST, 7 (78%) were late, and 2 (22%) early responders to omalizumab (p = 0.021). Of 6 patients scoring negative on ASST, 5 were early omalizumab responders and 1 did not respond. The PPV and NPV of the ASST for a \"late\" response to omalizumab were 78% and 100%, respectively. Total IgE were significantly higher in early responders. <b>Conclusions.</b> Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in egg allergy: a retrospective look at the utility of cut-off values.","authors":"P Botelho Alves, H Pires Pereira, I Carrapatoso, G Loureiro, I Farinha, M Lucena, T Freitas, A Todo Bom","doi":"10.23822/EurAnnACI.1764-1489.336","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.336","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food-dependent exercise-induced allergic reactions in Lipid Transfer Protein (LTP) hypersensitive subjects: new data and a critical reappraisal.","authors":"E Scala, V Villella, R Asero","doi":"10.23822/EurAnnACI.1764-1489.334","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.334","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Lipid transfer protein is the main cause of both primary food allergy and food-dependent exercise-induced allergic reactions (FDEIAR) in Italy. What characterizes LTP-hypersensitive patients with FDEIAR is still unclear. We investigated the key characteristics of LTP-hypersensitive patients with or without FDEIAR in a large cohort of individuals sensitized to this allergen. <b>Methods.</b> 1,203 food-allergic patients, diagnosed on the basis of unequivocal clinical history and presence of circulating food allergen-specific IgE were studied. Serum IgE reactivity was assessed using the Allergen ExplorerALEX^® system (Macroarray Diagnostics, Vienna, Austria). Association of specific IgE reactivities with FDEIAR was investigated, and patients with and without FDEIAR sensitized to LTP were compared. <b>Results.</b> 116 subjects (9.6%) had FDEIAR. Among these, 77 (66.3%) were LTP-reactors and 16 (13.8%) were sensitized to Tri a 19 (omega-5-gliadin). Different LTPs and omega-5-gliadin emerged as the sole allergens clearly associated with FDEIAR. Severity of allergic reactions was paralleled the level of specific IgE to LTPs. Patients with FDEIAR showed significantly lower IgE levels than their counterparts with food allergy at rest, and displayed nearly identical IgE levels regardless of the severity of allergic reactions induced by exercise. <b>Conclusions.</b> FDEIAR are associated with specific allergens. Specific IgE levels in LTP-hypersensitive patients with FDEIAR show an intermediate titer between those simply sensitized and those showing classic food allergy.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140038974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}